Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


TECOS evaluated the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.


Randomised, placebo-controlled global clinical trial performed in 14,735 patients who were enrolled between 2009 and 2012. TECOS was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 38 countries.


The results of TECOS were reported at the 2015 meeting of the ADA. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint of (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for unstable angina). Rates of hospitalization for heart failure, acute pancreatitis and pancreatic cancer did not differ between the two groups. The primary results paper is available here.

manuscript proposals

The TECOS Publications Committee are happy to review proposals for potential new manuscripts. Proposals should be submitted on a TECOS Trial Topic Request Form emailed to

Joint chairs


Rury Holman

Eric Peterson (Previously Robert Califf)


Merck Sharp & Dohme, a subsidiary of Merck


Merck Sharp & Dohme

Reference number

EudraCT 2008-006719-20

TECOS Publications